Publications

BibTex format

@article{Begum:2022:10.1016/j.jtocrr.2022.100376,
author = {Begum, P and Cui, W and Popat, S},
doi = {10.1016/j.jtocrr.2022.100376},
journal = {JTO Clin Res Rep},
title = {Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report.},
url = {http://dx.doi.org/10.1016/j.jtocrr.2022.100376},
volume = {3},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - gene rearrangements occur in 1% to 2% of NSCLC. Acquired "on-target" mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-line crizotinib, who responded to lorlatinib. The response was dramatic but short in duration.
AU  - Begum,P
AU  - Cui,W
AU  - Popat,S
DO  - 10.1016/j.jtocrr.2022.100376
PY  - 2022///
TI  - Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report.
T2  - JTO Clin Res Rep
UR  - http://dx.doi.org/10.1016/j.jtocrr.2022.100376
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35966191
VL  - 3
ER  -

Download

DrSanjayPopat

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)